Understanding response to stereotactic body radiotherapy in early-stage lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational trial aims to investigate the factors influencing the response of early-stage non-small cell lung cancer (NSCLC) patients to stereotactic body radiotherapy (SBRT). It will collect clinical, imaging, and biological data to develop models that predict treatment outcomes. The study includes tasks such as analyzing routine clinical data, performing quantitative imaging analysis, and conducting gene expression and proteomics studies. The goal is to identify why some patients respond well to SBRT while others do not, potentially leading to improved treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven NSCLC; all histologies will be considered eligible (e.g. squamous, adenocarcinoma, large cell carcinoma);
* American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) classification (8th Edition) clinical stage I-II;
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
* No absolute contraindications to either surgery (e.g. severe comorbidities) or SBRT (e.g. active connective diseases, severe pulmonary fibrosis);
* Ability and willingness to sign a written informed consent for treatment and study participation.

Exclusion Criteria:

* Prior diagnosis of invasive cancer (within 3 years before the diagnosis of ES-NSCLC);
* Mental diseases or psychiatric disorders preventing the acquisition of a valid informed consent.

Where it's running

• Istituto Europeo di Oncologia IRCCS
  Milan, Italy, Italy Recruiting
• Istituto Europeo di Oncologia (IEO) IRCCS
  Milan, Lombardy, Italy Recruiting

Study contacts

• Principal investigator: Stefania Volpe, MD — Istituto Europeo di Oncologia IRCCS
• Study coordinator: Stefania Volpe, MD, PhD
• Email: stefania.volpe@ieo.it
• Phone: 0039 02 57489037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enhanced COPD care for people being checked for lung cancer

  This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.

  Recruiting Region of Southern Denmark · Vejle · NCT07543601

• MK-1084 combined with other therapies for advanced non-squamous non-small cell lung cancer

  This trial tests whether MK-1084 given with other anti-cancer drugs can shrink tumors in people with advanced or metastatic non-squamous NSCLC who have a KRAS G12C mutation and have progressed after prior platinum chemotherapy and PD-(L)1 therapy.

  Recruiting at 29 sites Phase 1/2 Merck Sharp & Dohme LLC · Clermont, Florida and 28 other locations · NCT07286149

• Low-dose intestinal radiation plus immunotherapy for immune-resistant metastatic solid cancers

  This trial tests whether giving small doses of radiation to the intestine together with PD‑1/PD‑L1 immunotherapy can help people whose metastatic solid tumors have stopped responding to checkpoint inhibitors.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07071103

• Using advanced CT imaging to improve lung cancer diagnosis

  This study is testing a new type of CT scan to see if it can help doctors better diagnose lung cancer compared to regular CT and PET scans.

  Recruiting Copenhagen University Hospital at Herlev · Herlev, Capital Region · NCT06440616

• Evaluating a new imaging technique for lung cancer diagnosis

  This study is testing a new imaging technique during lung procedures to see if it helps doctors diagnose lung cancer more accurately in patients with suspicious lung lesions.

  Recruiting at 5 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · New York, New York and 4 other locations · NCT06079970

• Combining sintilimab, bevacizumab, and chemotherapy for lung cancer treatment before surgery

  This study is testing a new treatment that combines two medications and chemotherapy before surgery to see if it helps people with advanced lung cancer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT04973293

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.